- Home
- RSI vs SNDX Comparison
RSI vs SNDX Comparison
Compare RSI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSI | SNDX |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RSI | SNDX |
|---|---|---|
| Price | $17.10 | $21.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $21.71 | ★ $80.23 |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 02-17-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $1,063,702,000.00 | $111,304,000.00 |
| Revenue This Year | $21.96 | $617.40 |
| Revenue Next Year | $18.19 | $115.70 |
| P/E Ratio | $53.88 | ★ N/A |
| Revenue Growth | 23.15 | ★ 595.65 |
| 52 Week Low | $9.54 | $8.58 |
| 52 Week High | $22.65 | $22.73 |
Technical Indicators
Market Signals| Indicator | RSI | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 57.86 |
| Support Level | $16.66 | $20.00 |
| Resistance Level | $17.94 | $22.00 |
| Average True Range (ATR) | 0.93 | 1.11 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 19.81 | 82.22 |
Price Performance
Historical ComparisonAbout RSI Rush Street Interactive Inc.
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.